1 / 7

Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial

Phase 2a. Treatment Naïve and Treatment Experienced. Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial. Source: Lawitz E, et al. Lancet. 2014:383:515-23. Ledipasvir-Sofosbuvir + /- Ribavirin in Naïve & Experienced GT1 LONESTAR Trial: Features.

smithkaren
Download Presentation

Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1 LONESTAR Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2a Treatment Naïve and Treatment Experienced Sofosbuvir-Ledipasvir +/- Ribavirin in GT-1LONESTAR Trial Source: Lawitz E, et al. Lancet. 2014:383:515-23.

  2. Ledipasvir-Sofosbuvir +/- Ribavirin in Naïve & Experienced GT1LONESTAR Trial: Features Source: Lawitz E, et al. Lancet. 2014:383:515-23.

  3. Ledipasvir-Sofosbuvir +/- Ribavirin in Naïve & Experienced GT1LONESTAR: Study Design 0 8 12 20 24 Week Cohort ANaïven=60 n =20 SVR12 LDV-SOF n = 21 SVR12 LDV-SOF + RBV n = 19 SVR12 LDV-SOF n = 19 SVR12 Cohort BExperiencedn=40 LDV-SOF n = 21 SVR12 LDV-SOF + RBV Abbreviations: LDV-SOF= ledipasvir-sofosbuvir; RBV = ribavirin Drug DosingLedipasvir-Sofosbuvir: 90/400 mg fixed dose combination one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Lawitz E, et al. Lancet. 2014:383:515-23.

  4. Ledipasvir-Sofosbuvir +/- Ribavirin in Naïve & Experienced GT1LONESTAR Trial: Results LONESTAR: SVR 12, by Cohort and Treatment Regimen 19/20 21/21 18*/19 18/19 21/21 Cohort A: Treatment-Naive Cohort B: Experienced (with PI) *One patient lost to follow-up; LDV-SOF = ledipasvir-sofosbuvir; RBV = ribavirin; PI = protease inhibitor Source: Lawitz E, et al. Lancet. 2014:383:515-23.

  5. Ledipasvir-Sofosbuvir +/- Ribavirin in Naïve & Experienced GT1LONESTAR Trial: Adverse Events Source: Lawitz E, et al. Lancet. 2014:383:515-23.

  6. Ledipasvir-Sofosbuvir +/- Ribavirin in Naïve & Experienced GT1LONESTAR Trial: Conclusion Source: Lawitz E, et al. Lancet. 2014:383:515-23.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related